Xilio Therapeutics (XLO) Depreciation and Depletion (2020 - 2026)
Xilio Therapeutics (XLO) reported Depreciation and Depletion of $300000.0 for Q1 2026, down 40.0% on a YoY basis from $500000.0 in Q1 2025, and little changed sequentially from $300000.0 in Q4 2025.
Xilio Therapeutics (XLO) Depreciation and Depletion (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Depreciation and Depletion data on file, last reported at $300000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation and Depletion fell 40.0% year-over-year to $300000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 23.53% YoY), and the FY2025 full-year result was $1.5 million, down 6.25% from the prior year.
- Depreciation and Depletion was little changed at $300000.0 in Q1 2026, from $300000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $500000.0 in Q3 2022 to a low of $300000.0 in Q3 2025.
- A 5-year average of $405882.4 and a median of $400000.0 in 2022 frame the typical range for Depreciation and Depletion.
- Across the five-year window, Depreciation and Depletion surged 66.67% in 2022 and sank 40.0% in 2026, its largest moves.
- Tracing XLO's Depreciation and Depletion over 5 years: stood at $400000.0 in 2022, then changed by 0.0% to $400000.0 in 2023, then changed by 0.0% to $400000.0 in 2024, then dropped by 25.0% to $300000.0 in 2025, then changed by 0.0% to $300000.0 in 2026.
- Business Quant data shows XLO's Depreciation and Depletion at $300000.0 in Q1 2026, $300000.0 in Q4 2025, and $300000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 39.39 Mn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | - |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | - |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 2.20 Mn |
| 10 | Xilio Therapeutics | 148.07 Mn | -2.23 Mn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 400,000.00 |
| Dec 31, 2024 | 400,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |